<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230701058625N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-11</date_registration>
      <primary_sponsor>Dezfoul University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effectiveness of two treatment protocols: dexmedetomidine - propofol and midazolam - fentanyl - propofol in relieving pain in patients undergoing extracorporeal stone crusher</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of two treatment protocols dexmedetomidine - propofol and midazolam - fentanyl - propofol in relieving pain in patients undergoing lithotomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71036</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 40 patients who meet the criteria will enter the study and will be divided into two groups of 20 using computer random numbers. Group A, dexmedetomidine (a vial CC2mcg/200 diluted with CC50 normal saline and infused over 10 minutes, Blinding description: A nurse anesthetist who is not involved in this study will inject the drugs to the patients, then before and three hours after the operation, a blood sample will be taken by the researcher to measure P-Substance. None of the patients, as well as the researcher, will know what medicine was used for each patient.</study_design>
      <phase>4</phase>
      <hc_freetext>Patients with Calculus of kidney.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Group A will receive dexmedetomidine (a vial CC2mcg/200 diluted with CC50 normal saline and infused over 10 minutes. This form of infusion will be repeated if needed) and propofol (0.5 mg/kg). Intervention 2: Intervention group: Group B will receive midazolam (0.025 mg/kg), fentanyl (1 mcg/kg) and propofol (0.5 mg/kg).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Still undecided - no release schedule yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi Rajaeipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Justice corner, Post St., 15 Khordad Blvd., Dezful</address>
        <city>Dezfoul</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6461669969</zip>
        <telephone>+98 916 641 0103</telephone>
        <email>mehdi.rajaeipour@dums.ac.ir</email>
        <affiliation>Dezfoul University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi Rajaeipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Justice corner, Post St., 15 Khordad Blvd., Dezful</address>
        <city>Dezfoul</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6461669969</zip>
        <telephone>+98 916 641 0103</telephone>
        <email>mehdi.rajaeipour@dums.ac.ir</email>
        <affiliation>Dezfoul University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with kidney stones below 2cm and proximal ureter for ESWL aged 18 to 80 years with American Society of Anesthesiologists (ASA) physical status I, II or III who consent to participate in this study will be eligible for this study.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who do not agree to participate in this study
Patients with chronic liver failure
Patients who have a history of allergy to this drug or other alpha-adrenergic drugs
Patients with a history of bradycardia and low blood pressure
Patients with coagulation disorders
Patients with a history of allergy to drugs used to treat ESWL
Patients with mental disorders, nervous disorders and skin disorders (inflammation).
Patients with active infection
Patients who are pregnant
Patients who have uremia
Patients with BMI &gt; 25
Patients who have used painkillers 12 hours before visiting
Patients who have pain before visiting</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N20.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Calculus of kidney</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Group A will receive dexmedetomidine (a vial CC2mcg/200 diluted with CC50 normal saline and infused over 10 minutes. This form of infusion will be repeated if needed) and propofol (0.5 mg/kg)</i_keyword>
      <i_keyword>Intervention group: Group B will receive midazolam (0.025 mg/kg), fentanyl (1 mcg/kg) and propofol (0.5 mg/kg).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Plasma level of Substance P in patients. Timepoint: At the beginning of the study and one week after lithotomy of the patients. Method of measurement: Measuring the Plasma level with ELISA.</prim_outcome>
      <prim_outcome>Pain. Timepoint: At the beginning of the study and one week after lithotomy of the patients. Method of measurement: The person is shown a scale from 0 to 10 and the person gives a score from 0 to 10 on the level of pain felt. (Visual Analogue Scale).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood pressure. Timepoint: Two times, before ESWL and one week after ESWL. Method of measurement: Manual sphygmomanometer.</sec_outcome>
      <sec_outcome>Respiratory rate. Timepoint: Two times, before ESWL and one week after ESWL. Method of measurement: clinical examination.</sec_outcome>
      <sec_outcome>Nausea and Vomiting. Timepoint: Two times, before ESWL and one week after ESWL. Method of measurement: Event occur.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dezfoul University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-09</approval_date>
        <contact_name>Research Ethics Committees of Dezful University of Medical Sciences</contact_name>
        <contact_address>Justice corner, Post St., 15 Khordad Blvd., Dezful Dezfoul Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
